TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05464212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG Guided Greater Occipital Nerve Block
Description: With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: USG Guided Greater Occipital Nerve Block and Pulsed Radiofrequency
Description: With 0.5 Hz sensorial stimulation, a 5-cm-long radiofrequency needle with a 0.5 cm active tip was advanced under ultrasound guidance in both pulsed PRF and nerve block groups. USG probe was located to medial one-third of the superior nuchal line between the occipital tubercle and mastoid process under sterile conditions. Finally, the placement of the needle was verified by Doppler imaging of the occipital artery. A 0.3-0.5 Hz sensory stimulus was given with the RF device, and the paresthesia sensation in the patient's occipital nerve dermatome was questioned, and location verification was performed. Then, GON block was performed in all patients by administering 5mg bupivacaine through a PRF needle. After the GON block, the PRF neuromodulation was applied at 42 degrees for 4 minutes in the GONB-PRF group. In the GONB group, the PRF generator was set for 4 minutes, and the time was waited, but no pulse was given.
Study: NCT00598897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin, rifabutin
Description: Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
Study: NCT04446689

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback
Description: This intervention will be measured by the Software Emwave Pro Plus during 4 weeks, which send out a sign captured by a non-invasive sensor such as an ear lobe fixed photoplethysmograph.
Study: NCT02957292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (13,5 mg) intrauterine device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cooper (380mm2) intrauterine device
Study: NCT04376814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: Patients will be given a stat dose of 1600mg Favipiravir tablets for the first time, and for next time they will be given 600mg of favipiravir tablets three times per day for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: 200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 200mg of Hydroxychloroquine two times per day will be given to patients for seven days in Test group, and Patients in Control group will be given a stat dose of 400mg Hydroxychloroquine tablets two times per day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lopinavir / Ritonavir
Description: Patients will be given 200/50 mg of Lopinavir / Ritonavir two times per day for seven days.
Study: NCT01895517

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: LBC
Description: Cervical cancer screening by using liquid based cytology as a standard screening modality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LBC plus HPV DNA testing
Description: Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
Study: NCT03201614

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-CP HA Kit
Description: Patients randomized in this group will receive two injections of platelet-rich plasma/hyaluronic acid prepared with the A-CP HA Kit at Day 0 and Month 2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArthroVisc 40
Description: Patients randomized in this group will receive two injections of hyaluronic acid only (ArthroVisc 40) at Day 0 and Month 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized in this group will receive two injections of a saline placebo at Day 0 and Month 2
Study: NCT00880490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT005
Description: single dose, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT005
Description: single dose, inhaled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled PT005
Description: single dose, inhaled

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inhaled placebo
Description: single dose, inhaled

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol Fumarate 12 mcg (Foradil Aerolizer)
Description: single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
Study: NCT01769391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered IV
Study: NCT02607969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home program
Description: Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home program
Description: Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
Study: NCT00505687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Rotigotine transdermal patches:~10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)~Optimal dosing:~The maximum rotigotine dose allowed is 16 mg/24 hours.
Study: NCT04319809

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Object recognition subsystem
Description: The object recognition subsystem is an add-on to the Argus II retinal prosthesis system. in the early stage of the study the subsystem will run on a separate processor; in the later stage the subsystem will run in the Argus II user's video processing unit.
Study: NCT02341274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Bioequivalence study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Bioequivalence study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Bioequivalence study

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Bioequivalence study
Study: NCT05035108

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: hiHep bioartificial liver therapy
Description: HiHep cell bioartificial liver treatment was performed 24-48 hours after extensive hepatectomy. Temporary hemodialysis tube for large vein (jugular vein or femoral vein) is indwelled before treatment. Before treatment, prepare hiHeps-BAL in a biological safety cabinet that meets clinical standards, connect the corresponding tubing to the Jianfan DX-10 blood purification machine, and prefill with heparin saline. Half an hour before treatment, the patient was pre-heparinized (heparin about 600iu) and dexamethasone to prevent allergic reactions. The patient enters the ICU, the monitor is connected to the corresponding pipeline, the arterial pump 120-160ml/min, the slurry pump 30-40ml/min, the circulating pump 75-100ml/min, the duration is 6-9h.
Study: NCT02329808

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
Study: NCT02343237

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic treatment
Description: osteopathic sessions of 20 minutes

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Factitious osteopathic treatment
Description: 6 factitious osteopathic sessions of 20 minutes
Study: NCT02329808

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.

Intervention type: PROCEDURE
Intervention: blood drawing
Description: The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
Study: NCT01128517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maternal education on complementary feeding
Description: CF education to the mothers in intervention arm.~* Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 \& 2006).~* First session --\> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.~* Second session --\>breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.~* Third session --\> previous sessions recall. protein based and iron rich food encouragement.~* The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Maternal education on complementary food
Study: NCT03539614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: This is an antagonist of the alpha1 receptor for noradrenaline. It is FDA approved for the treatment of hypertension, and has also been used for benign prostatic hypertrophy (BPH). Most recently, it has been found to be helpful for symptoms of PTSD in some but not all participants.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: This is a capsule containing an inert substance, in order to provide blinding to participants and study staff of when participants are on active medication and when they are not during the later portions of the trial.
Study: NCT03314584

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Description: Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
Study: NCT01769391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered IV
Study: NCT00329979

Intervention type: BEHAVIORAL
Intervention: vascular access site
Description: Randomized vascular access site

Intervention type: BEHAVIORAL
Intervention: vascular access site
Description: Randomized vascular access site
Study: NCT03386929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: A human antibody of the immunoglobulin gamma-1 isotype that specifically targets and blocks the Programmed Death ligand (PD-L1) for PD-1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: A selective oral (tablet) inhibitor of tyrosine kinases Vascular Endothelial Growth Factor (VEGF) receptors 1, 2, and 3. These receptors are implicated in pathologic angiogenesis, tumor growth and cancer progression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: A selective, reversible oral (capsule) inhibitor of cyclin-dependent kinases (CDK) 4 and 6. The inhibition of CDK 4/6 blocks DNA synthesis by prohibiting progression of the cell cycle from G1 to S phase.
Study: NCT03076450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound
Description: Adjust PEEP real-time in term of LUS-RAS chang.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Maximum Oxygenation
Description: Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
Study: NCT00258518

Intervention type: PROCEDURE
Intervention: mechanical ventilation/CT Scan
Description: evaluation of pleural effusion and respiratory mechanics, CT scan
Study: NCT06015594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients treated with metformin
Study: NCT04084769

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine MenACYW Conjugate vaccine
Description: Pharmaceutical form: Solution for injection Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Group B vaccine (Trumenba®)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal group B vaccine (Bexsero®)
Description: Pharmaceutical form: Suspension for injection in pre-filled syringe Route of administration: IM
Study: NCT02761070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT05486754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral stress management
Description: Participants will receive in-person weekly stress management group sessions (3-8 participants) for two hours per week for ten weeks total. Each session will consist of a half hour of relaxation training and one and a half hours of stress management skill training, including coping effectiveness training, anger management, assertiveness training, and stress awareness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducational Control
Description: Participants will receive one four-hour seminar in-person groups (3-8 participants) of educational information related to prostate cancer and abbreviated psychological information provided in cognitive behavioral stress management.
Study: NCT04274751

Intervention type: DEVICE
Intervention: Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation

Intervention type: DEVICE
Intervention: Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation
Study: NCT01247558

Intervention type: OTHER
Intervention: Metanx® (a medical food)
Description: Patient cohort compliant on Metanx® BID therapy for \>120 days

Intervention type: OTHER
Intervention: Not treated with Metanx®
Description: Non-treated comparative cohort
Study: NCT03538054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: (1)10 mg, by mouth, twice daily every 12 hours.
Study: NCT00815698

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suture
Description: suture for mesh fixation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no suture
Description: no suture for mesh fixation, because we use a self-adhesive mesh
Study: NCT00412542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 100 mg PO (by mouth) daily for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPT-11
Description: 125 mg/m\^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Dynamic MRI scan with dye injection through vein, every 6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Tests (QST)
Description: QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
Study: NCT03538054

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule, by mouth, twice daily every 12 hours.
Study: NCT03650322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga
Description: 12 weeks, total of 150 minutes of exercise per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching and Toning
Description: 12 weeks, total of 150 minutes of exercise per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Walking
Description: 12 weeks, total of 150 minutes of exercise per week.
Study: NCT03083405

Intervention type: DRUG
Intervention: Opipramol
Description: The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
Study: NCT01976195

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide 150mg per day, 15 consecutive days
Study: NCT02550262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.0625% Bupivacaine plus fentanyl 2mcg/ml